VIR Stock Soars Over 10% Overnight, Eyes Best Year Ever — Hepatitis Win Sparks Buyout Buzz And Bigger Bullish Bets
All 28 Solstice patients completing 96 weeks had undetectable virus. Eclipse-1 met all endpoints, with 79% of treated patients reaching undetectable virus and 44% also achieving normal ALT levels after 48 weeks. Eclipse 2 and Eclipse 3 results are expected in early 2027, helping an FDA filing around midyear. Vir and Astellas plan pivotal prostate-cancer … Read more